Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap

Completed · Phase 2 · Has a placebo group

Conditions studied: Leiomyoma

In brief

The study is performed to assess the efficacy and safety of different doses of BAY1002670 in subjects with uterine fibroids. The dose-response relationship will be evaluated. Further, the study aims to establish a population pharmacokinetic/pharmacodynamic relationship for BAY1002670 in subjects with uterine fibroids. To assess the efficacy of BAY1002670 the interchangeability of menstrual pictogram and alkaline hematin method for the judgement of menstrual blood loss will be assessed.

Key facts

Study ID

NCT02131662

Run by

Bayer

People needed

309

Starts

2014-05-15

Expected to finish

2016-05-04

Last updated by the study team

2017-12-08

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Signed and dated informed consent
• Diagnosis of uterine fibroid(s) documented by transvaginal or abdominal ultrasound at screening with at least 1 fibroid with largest diameter 3.0 cm
• 18 to 50 years of age at the time of screening
• Heavy menstrual bleeding >80 mL documented by MP during the bleeding episode following the screening visit
• Normal or clinically insignificant cervical smear not requiring further follow-up
• An endometrial biopsy performed at the screening visit 1 (Visit 1), without significant histological disorder such as endometrial hyperplasia or other significant endometrial pathology
• Use of a non-hormonal barrier method of contraception starting at the bleeding episode following the screening visit 1 (Visit 1) until the end of the study
• Good general health (except for findings related to uterine fibroids)

You may not qualify if…

• Pregnancy or lactation
• Uterine fibroid with largest diameter >10.0 cm
• Hypersensitivity to any ingredient of the study drug
• Laboratory values outside inclusion range before randomization and considered as clinically relevant
• Hemoglobin values <6 g/dL or any condition requiring immediate blood transfusion (subjects with hemoglobin values <10.9 g/dL will receive iron supplementation)
• Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug

Where it is running

• Study site — Tucson, Arizona, United States
• Study site — San Diego, California, United States
• Study site — San Diego, California, United States
• Study site — Denver, Colorado, United States
• Study site — Southington, Connecticut, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Gainesville, Florida, United States
• Study site — Jacksonville, Florida, United States
• Study site — Plantation, Florida, United States
• Study site — South Miami, Florida, United States
• Study site — Sandy Springs, Georgia, United States
• Study site — Naperville, Illinois, United States
• Study site — Newburgh, Indiana, United States
• Study site — Marrero, Louisiana, United States
• Study site — Lincoln, Nebraska, United States
• Study site — Moorestown, New Jersey, United States
• Study site — Neptune City, New Jersey, United States
• Study site — New Brunswick, New Jersey, United States
• Study site — New York, New York, United States
• Study site — Durham, North Carolina, United States
• Study site — Raleigh, North Carolina, United States
• Study site — Cleveland, Ohio, United States
• Study site — Columbus, Ohio, United States
• Study site — Portland, Oregon, United States
• Study site — Mesa, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.